Daclatasvir/sofosbuvir and ribavirin 800mg flat dose is highly efficacy and safe in genotype 3 compensated and decompensated cirrhotic patients: The CLEO experience

Authors :: F. Ceccherini Silberstein
G. Cerasari
C.F. Perno
A. Moretti
L. Fondacaro
Giorgio Barbarini
F. Chiesara
Anna Claudia Pellicelli
R. Villani
C. D'Ambrosio
F.R. Ponziani
Sergio Babudieri
Maurizio Pompili
Rodolfo Sacco
Roberto Gulminetti
Pierluigi Tarquini
V. Pace Palitti
Vincenzo Messina
Antonio Izzi
V.C. Di Maio
F. Di Candilo
Valerio Giannelli
Vincenzo Iovinella
Serena Dell'Isola
Source :: Digestive and Liver Disease. 49:e64
Publication Year :: 2017
Publisher :: Elsevier BV, 2017.

Subjects :: medicine.medical_specialty
Hepatology
Sofosbuvir
business.industry
Ribavirin
Gastroenterology
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
chemistry
030220 oncology & carcinogenesis
Internal medicine
Genotype
medicine
030211 gastroenterology & hepatology
business
medicine.drug

Tools